Chiasma Announces FDA Approval of MYCAPSSA® (Octreotide) Capsules, the First and Only Oral Somatostatin Analog
MYCAPSSA is indicated for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide Conference call and webcast scheduled today at 2 pm ET NEEDHAM, Mass., June 26, 2020 (GLOBE …